NO_LONGER_AVAILABLENot Applicable

Treatment Use of 3,4-Diaminopyridine

United States

Plain-language summary

This protocol provided 3,4 diaminopyridine (DAP) under a treatment-use IND to patients with congenital myasthenic syndrome (CMS). It is now closed.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of congenital myasthenic syndrome (CMS) * Women of childbearing potential must have negative pregnancy test and agree to practice adequate contraception while taking DAP * Must be competent to give consent Exclusion Criteria: * Known seizure disorder * Pregnancy * Known cardiac arrhythmia or evidence of significant arrhythmia on screening ECG * Known hepatic, renal or hematologic disease

Trial details

NCT IDNCT01765140

SponsorVern C. Juel, M.D.

Sponsor typeOTHER

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Myasthenic Syndromes, Congenital trials